MORPH-A: Multidisciplinary Obesity Rehabilitation & Psychophysical Health and Awareness

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention combines multidisciplinary rehabilitation with routine clinical management to support adults with obesity and cardiometabolic risk factors. Eligible participants start GLP-1 or GLP-1/GIP therapy and engage in a 12-week program designed to address physical activity, nutrition, and psychosocial factors. The study emphasizes outpatient care, structured exercise, and ongoing care coordination within an Italian clinical setting. Participant suitability includes language comprehension, stability for physical activity, and informed consent. Outcomes focus on feasibility, adherence, and potential improvements in health risk profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* Class I or II obesity assessed at T0 with comorbid risk factors (EOSS \> or equal to 2) for which an SIO appropriateness form with a score \> or equal to 20 has been completed
* Patients who agree to begin treatment with a GLP-1 or GLP-1/GIP analog
* Fit for physical exercise
* Willingness to participate in the 12-week program
* Understanding of the Italian language and ability to complete the questionnaires
* Understanding of the research objectives and ability to provide informed consent.

Exclusion Criteria:

* Age \< 18 years;
* Non-Italian education, illiteracy, or relapse into illiteracy;
* Low motivation/interest or refusal to undergo assessment;
* Absence of comorbidities (EOSS \< or equal to 1)
* Major psychiatric disorders, substance abuse;
* Obesity secondary to genetic and endocrinological disorders (e.g., hypercortisolism, acromegaly, overt hypothyroidism);
* Functional limitations that prevent participation in physical therapy sessions;
* Concurrent participation in other trials that could potentially interfere with the outcomes of this study.

Where it's running

• Istituti Clinici Scientifici Maugeri, IRCCS
  Pavia, Italy Recruiting

Study contacts

• Principal investigator: Antonia Pierobon — Istituti Clinici Scientifici Maugeri IRCCS
• Study coordinator: Antonia Pierobon
• Email: antonia.pierobon@icsmaugeri.it
• Phone: +390385247255

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.